On May 13, 2022 Jiangsu Hengrui Medicine reported that a combination of its PD-1 and VEGFR inhibitors met its efficacy endpoints in patients with newly diagnosed liver cancer, outperforming Bayer’s Nexavar (Press release, Jiangsu Hengrui Medicine, MAY 13, 2022, View Source [SID1234614556]). The global Phase III trial tested the combination therapy for overall survival. Hengrui has already filed for China approval of the combination and plans to seek US approval as well. Hengrui and its US partner Elevar started US trials for the combination in 2019, so they have efficacy data in US patients. The lack of that data caused the US to reject two China-developed immunotherapies recently.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!